On 20th January 2025, President Donald Trump signed two orders that initiated a war against Big Pharma! The first was the US withdrawal from the World Health Organization (WHO) and the second was federal gender identity policies. Both of these decisions begin the Reset Era of World Politics. Moreover, these measures significantly impact the pharmaceutical industry, U.S. citizens, and the global community. Let’s unravel!
Donald Trump and WHO’s Mismanagement
President Trump has just withdrawn the 🇺🇸 from the World Health Organization (WHO)
I’m sure big pharma and the globalists aren’t too happy about this.
— Patrick Bet-David (@patrickbetdavid) January 21, 2025
President Donald Trump signed the order to withdraw the United States from the WHO. The withdrawal cites concerns over financial mismanagement and inefficacy as seen during the COVID-19 pandemic. This decision mirrors a similar action taken by Donald Trump in July 2020. However, Trump lost the 2020 US elections, and in January 2021, the Biden administration reversed the decision.
The WHO withdrawal is expected to take effect within a year, during which the US government funds and support to the WHO will be paused.
The US contributes 15% of the total WHO funds. However, Donald Trump alleges that most of the decision-making is done through a pro-China perspective, as witnessed by their inability to blame China for the pandemic. Thus, Trump’s USA refuses to be the WHO’s cash cow. Contrarily, critics argue that this move would create a funding gap in WHO which could be exploited by China.
Day one: 🔥🔥🔥
Trump withdraws from the deep state controlled World Health Organisation!! This is big blow to Davos globalists and their new world order plans of totalitarian controls. Not just this WHO is an evil organisation which is nothing but an arm of pharmaceutical… pic.twitter.com/KsgtdwWJEt— Ritu #सत्यसाधक (@RituRathaur) January 21, 2025
Big Pharma benefitted from US funding of the WHO! The WHO allowed pharma conglomorates to dictate global health policies. Moreover, it allowed globalist agenda to override the need of developing nations. The vaccine research and distribution programs funneled government funds into private pharmaceutical companies. The US withdrawal from the WHO will disrupt the international drug chokehold of Big Pharma. Thereby, potentially reducing Big Pharma’s influence on the global economies and governments.
Donald Trump Ends Wokeness in Government
BREAKING: Trump says his government will be eliminating any and all forms of DEI and only recognize 2 genders pic.twitter.com/pxKnY5e0e2
— End Wokeness (@EndWokeness) January 20, 2025
Another order signed by Donald Trump on his first day back in office aims to redefine federal recognition of gender. The new administration no longer recognizes only strictly male or female genders, based on birth assignment. This action effectively reverses previous policies that acknowledged a spectrum of gender identities. Moreover, it saves women from having their private spaces intruded into by mentally confused men dressed in skirts! From women sports to women prisons, the policy shall reverberate through the USA!
Trump is signing an Executive Order that officially defines the words man and woman, removes gender ideology from government, bans men from women’s prisons, requires that a person’s biological sex is on their government ID, protects kids in school from trans indoctrination, and…
— Matt Walsh (@MattWalshBlog) January 20, 2025
Apart from impacting federal documents, healthcare provisions, and housing policies, the order impacts the deep pockets of Big Pharma.
Big pharma is highly incentivized to get as many people as possible to become transgender as early as possible.
This is why we aren’t allowed to point out that endocrine disrupting chemicals in all our food and products is deeply tied to the massive spike in transgenderism. https://t.co/1o8w5xnMr3
— Ian Carroll (@IanCarrollShow) January 5, 2025
Big Pharma was turning confused children and mentally unstable adults into lifelong patients. Under the Biden administration, the US government’s health insurance paid for sex change hormones, puberty blockers, and gender reassignment surgeries. Consequently, many Americans were rendered disfigured, infertile, and dependent on Big Pharma’s doles of medicine. Notably, major pharmaceutical companies have been reported to earn significant profits from gender transition-related medications and surgeries.
Currently, Donald Trump’s action on gender identity is indirect and restricted to US government policies. However, it sends signals of imminent death to Big Pharma that benefits from turning US children and adults into patient numbers.
Implications of Trump’s War on Big Pharma – USA and Beyond
For US citizens, these policy changes may lead to a reduction in viral wokeism and LGBTQIA+ agenda. The redefinition of gender identity at the federal level could result in the denial of coverage for gender-affirming treatments, affecting the well-being of transgender individuals. Several Americans will need to get their passports reissued if their passport records their gender as anything other than male or female.
Globally, the US exit from the WHO could hinder the US’s health collaborations with other nations. The absence of US funding and support may weaken the WHO’s capacity to dictate terms of global health initiatives. The unequal and biased Pandemic treaty of the WHO shall be firmly and finally rejected.
Opportunities for Bharat
Bharat can leverage this shift by strengthening its pharmaceutical sector to fill potential gaps in the global market. With the US stepping back from the WHO, Indian pharmaceutical companies have an opportunity to increase their participation in global health initiatives, potentially expanding their market share.
Additionally, Bharat can play a more prominent role in international health organizations, contributing to global health policy and research. By increasing its involvement, India can help shape health policies that align with its interests and showcase its capabilities in the global health arena.
President Donald Trump’s decisive actions mark a new chapter in US policy, with far-reaching consequences for the global pharmaceutical industry. As the world adjusts to these changes, Bharat as a unique opportunity to step up and play a more significant role in global health and policy-making.